|کد مقاله||کد نشریه||سال انتشار||مقاله انگلیسی||ترجمه فارسی||نسخه تمام متن|
|5666950||1407839||2017||3 صفحه PDF||سفارش دهید||دانلود کنید|
- The efficacy of aminoglycosides against multi-drug-resistant (MDR) bacilli is preserved.
- Aminoglycosides cause frequent adverse events.
- The average duration of amikacin IV treatment is usually less than recommended by World Health Organization.
- The place of amikacin should be re-evaluated, including its route of administration.
Second-line injectable antituberculosis drugs (aminoglycosides and capreomycin) are the main drugs used in the management of resistant tuberculosis. Their preserved efficacy in the case of multi-drug-resistant bacillus is counterbalanced by frequent adverse events. Adverse events are linked to the drugs themselves and to the recommended 8-month period of parenteral administration. In numerous countries facing a high incidence of multi-drug-resistant tuberculosis, treatment is administered by intramuscular injection. This procedure is painful and restrictive, and therefore treatment adherence is limited. This study reports the follow-up of 11 patients diagnosed with multi-drug- and extensively-resistant tuberculosis and treated with parenteral amikacin, and discusses the role of amikacin in the treatment of resistant tuberculosis.
Journal: International Journal of Antimicrobial Agents - Volume 50, Issue 2, August 2017, Pages 252-254